OVN Stock Overview
Oventus Medical Limited, a medical device company, develops and commercializes oral appliances for the treatment of obstructive sleep apnoea (OSA) and snoring in Australia, Canada, and the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.095|
|52 Week High||AU$0.28|
|52 Week Low||AU$0.077|
|1 Month Change||15.85%|
|3 Month Change||-17.39%|
|1 Year Change||-62.75%|
|3 Year Change||-68.85%|
|5 Year Change||-86.62%|
|Change since IPO||-86.43%|
Recent News & Updates
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Oventus Medical Limited's (ASX:OVN) CEO For Now
Shareholders of Oventus Medical Limited ( ASX:OVN ) will have been dismayed by the negative share price return over the...
|OVN||AU Medical Equipment||AU Market|
Return vs Industry: OVN underperformed the Australian Medical Equipment industry which returned -6.5% over the past year.
Return vs Market: OVN underperformed the Australian Market which returned 10.4% over the past year.
|OVN Average Weekly Movement||8.9%|
|Medical Equipment Industry Average Movement||8.5%|
|Market Average Movement||8.4%|
|10% most volatile stocks in AU Market||15.2%|
|10% least volatile stocks in AU Market||3.6%|
Stable Share Price: OVN is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: OVN's weekly volatility (9%) has been stable over the past year.
About the Company
Oventus Medical Limited, a medical device company, develops and commercializes oral appliances for the treatment of obstructive sleep apnoea (OSA) and snoring in Australia, Canada, and the United States. The company offers O2Vent Optima, a 3D-printed nylon oral appliance for OSA patients; and ExVent, a valve accessory that fits into the open airway of the O2Vent Optima device. The company was incorporated in 2015 and is headquartered in Indooroopilly, Australia.
Oventus Medical Fundamentals Summary
|OVN fundamental statistics|
Is OVN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OVN income statement (TTM)|
|Cost of Revenue||AU$687.91k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.041|
|Net Profit Margin||-902.36%|
How did OVN perform over the long term?See historical performance and comparison
Is Oventus Medical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OVN (A$0.1) is trading below our estimate of fair value (A$1.13)
Significantly Below Fair Value: OVN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OVN is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: OVN is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OVN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OVN is good value based on its PB Ratio (1.8x) compared to the AU Medical Equipment industry average (4.4x).
How is Oventus Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OVN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: OVN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: OVN's is expected to become profitable in the next 3 years.
Revenue vs Market: OVN's revenue (78.3% per year) is forecast to grow faster than the Australian market (4.9% per year).
High Growth Revenue: OVN's revenue (78.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OVN's Return on Equity is forecast to be high in 3 years time (24.9%)
How has Oventus Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OVN is currently unprofitable.
Growing Profit Margin: OVN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OVN is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accelerating Growth: Unable to compare OVN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OVN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: OVN has a negative Return on Equity (-77.92%), as it is currently unprofitable.
How is Oventus Medical's financial position?
Financial Position Analysis
Short Term Liabilities: OVN's short term assets (A$10.5M) exceed its short term liabilities (A$2.1M).
Long Term Liabilities: OVN's short term assets (A$10.5M) exceed its long term liabilities (A$359.8K).
Debt to Equity History and Analysis
Debt Level: OVN is debt free.
Reducing Debt: OVN has no debt compared to 5 years ago when its debt to equity ratio was 37.2%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OVN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: OVN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11.1% each year
What is Oventus Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OVN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OVN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OVN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Christopher Patrick Hart, also known as Chris, has been Chief Executive Officer and Managing Director of Oventus Medical Limited since August 30, 2018. Dr. Hart is the Co-Founder of Oventus Medical Lim...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD1.31M) is above average for companies of similar size in the Australian market ($USD291.63K).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
Experienced Management: OVN's management team is considered experienced (2 years average tenure).
Experienced Board: OVN's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52.7%.
Oventus Medical Limited's employee growth, exchange listings and data sources
- Name: Oventus Medical Limited
- Ticker: OVN
- Exchange: ASX
- Founded: 2015
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: AU$20.788m
- Shares outstanding: 241.73m
- Website: https://o2vent.com
- Oventus Medical Limited
- 1 Swann Road
- Suite 1
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/17 07:03|
|End of Day Share Price||2022/01/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.